key: cord-0697610-a1lgn4bp
authors: Yu, Ran; Li, Peng
title: Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking
date: 2021-12-10
journal: J Virol Methods
DOI: 10.1016/j.jviromet.2021.114424
sha: 35ecab0d0d2222bbf7a0fc16aafee8f0cc1d02db
doc_id: 697610
cord_uid: a1lgn4bp

The novel coronavirus disease has spread rapidly and caused sustained pressure on economic and medical resources to many countries. Vaccines and effective drugs are needed to fight against the epidemic. Traditional Chinese Medicine (TCM) plays an important and effective role in the treatment of COVID-19. Therefore, the active components of TCM are potential structural basis for the discovery of antiviral drugs. Through screening by molecular docking, Oleanolic acid, Tryptanthrin, Chrysophanol and Rhein were found to have better spike protein and ACE2 inhibitory activity, which could block the invasion and recognition of SARS-CoV-2 at the same time, should be investigated as antiviral candidates.

The novel coronavirus disease which was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] has brought out a worldwide epidemic [2] since its outbreak in 2019. SARS-CoV-2 is an enveloped positive-sense RNA singlestranded β-CoV [3] , similar to severe acute respiratory syndrome of coronavirus (SARS-CoV) or the middle east respiratory syndrome-related coronavirus (MERS-CoV) in 2003 and 2012 [4] . COVID-19 has caused persistent economic and medical pressure to many countries.

Vaccine and effective drugs are the key tools to fight against COVID-19, especially in face of the continuous emergence of virus mutants.

The genomic RNA of SARS-CoV-2 is 29.9 kb, in which there are 11 open reading frames (ORF). ORF1a and ORF1ab encode the replicase polyproteins which are processed into approximately 15 non-structural proteins [5] . Other ORF is responsible for the production of four structural proteins (spike protein, nucleocapsid protein, membrane protein, and envelope protein) [6] . The spike protein (S) is a trimeric transmembrane glycoprotein, each monomer consists subunits S1 and S2.

The renin-angiotensin-aldosterone system (RAAS) is the major mechanisms of hypertension [7] . Angiotensin converting enzyme (ACE) secreted by the lungs and the epithelial cells is the main regulator of RAAS, cleave the short peptide angiotensin I to angiotensin II which leads to arterioles constriction and blood pressure increase [8] .

Angiotensin-converting enzyme 2 (ACE2) distributed at the cellular surface of tissues, is a transmembrane protein with the extracellular N-terminal and intracellular C-terminal domains [9] . The structure of ACE2 consists transmembrane domain, Zn 2+ binding domain and a signal J o u r n a l P r e -p r o o f peptide [10] . ACE2 is a potential regulator of RAAS [11] , which could convert Ang II to Angiotensin (1-7) [12] . ACE2 plays a protective role in reducing hypertension and activating anti-inflammatory pathways after tissue injury [13] . ACE2 is the main receptor of SARS-CoV-2. Besides ACE2, DPP-4 may also be utilized by spike glycoproteins as entry receptor [14] . The first step for the invasion of virus is binding to ACE2 [15] , followed by the division of S1 / S2 subunit [16] which priming the integration of the virus and host cell membranes [17] . The receptor-binding domain (RBD) of SARS-CoV-2 located in S1 subunit, includes a core domain known as the receptor-binding motif (RBM). RBM binds to the viral binding motif of ACE2 [18] , and mediates the recognition of virus to receptor ACE2 [19] . SARS-CoV-2 recognizes ACE2 with RBD of S1, and downregulates the expression of ACE2 [20] .

SARS-CoV-2 and SARS-CoV use the same entry receptor ACE2 [21] , however, the binding affinity of SARS-CoV-2 for ACE2 receptor appears to be 10 times stronger [22] .

Compared with SARS-CoV, SARS-CoV-2 is more infectious. In the SARS-CoV-2 infection, viral entry into the host cells depends on the presence of ACE2 and transmembrane protease serine type 2 (TMPRSS2). Cells with a relatively high expression of ACE2 should be considered as potential SARS-CoV-2 infection sites [23] . Higher ACE2 expression is correlated with higher SARS-CoV-2 viral infectivity [24] . Since ACE2 serves as the main entry point for SARS-CoV-2 infection, more severe symptoms may be related to higher viral load in affected cells due to easier viral entry [25] . So targeting ACE2 expression can be used as a treatment for COVID-19 [26] . Inhibition the entry of SARS-CoV-2 into the host cell via the ACE 2 receptors maybe an effective strategy to antagonize COVID-19 [27] . ACE inhibitors have been used in the treatment of hypertension. ACE2 and ACE share the similar protein sequences [28] , however, the ACE inhibitors could not block ACE-2 [29] . ACE inhibitors have been reported to increase ACE2 expression in RAAS [30] . Therefore, it is necessary to find specific antagonists against ACE2 to resist SARS-CoV-2 infection. Several J o u r n a l P r e -p r o o f key residues of ACE2 may affected the interaction with spike protein of SARS-CoV-2. The N720D variant of ACE2 affected the stability and flexibility by increasing the level of motion in the loop region, resulting in a more favorable site for TMPRSS2 [31] . ACE2 residues E564, R559, N556 were found in the interaction with spike protein [32] . The S1 subunit of CoV could be further divided into an N-terminal domain (NTD) and a C-terminal domain (CTD), both NTD and CTD can be used as RBD to recognize the receptor of host cell. As to SARS-CoV-2, the viral CTD was applied to binding with ACE2 [33] . The RBM has a high degree of structural plasticity to accommodate amino acid changes without disrupting ACE2 binding [34] . There are few variations at the RBM that drastically alter the binding affinity of RBD to the ACE2 in SARS-CoV2 [35] .

Traditional Chinese medicine (TCM) has been used to reduce symptoms and slow down the course of COVID-19 [36] . The effectiveness and importance of TCM during the treatment of SARS-CoV-2 infection has already been demonstrated [37] . A lot of plants belonging to TCM with natural antiviral effect, such as Forsythia suspense, Isatis root, Schisandra chinensis, Licorice and Lithospermum, etc.. Quercetin distributed in a variety of TCM and vegetables is a flavonoid compound with anti-viral activity against a variety of viruses [38, 39] . Glycyrrhizic acid is a compound isolated from the TCM licorice with significant antiviral and bactericidal effects [40] . Andrographolide is a component of TCM with wide biological activities including immunity regulation, antivirus, antibacterial [41] . Schizandrin, Ursolic acid and Baicalin [42] also have different antioxidant, antiallergic and antiviral activity [43] .

In addition, Coumarin [44] and Radix Isatidis [45] are also active ingredients with antiviral effect.

SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, and the domain is relatively conservative, which can be used as drug design targets. A putative target on the host transmembrane to interfere with the virus RBD is a J o u r n a l P r e -p r o o f potential site. Blocking or manipulating the SARS-CoV2-ACE2 binding interface may offer the best method to fight against the virus [46] . A spike glycoprotein / ACE2 dual antagonist could bind to RBD, and compete with the binding of SARS-CoV-2 to ACE2 to prevent the virus entry by two mechanisms. In this study, components of TCM with antiviral activities, that can effectively inhibit spike protein as well as protect the viral binding site of ACE2

receptor were used to screen for the dual antagonists against COVID-19 by molecular docking.

The interactions of amino acid residues near the binding site of SARS-CoV-2 RBD determines the affinity with receptor. The residues L455, F486, Q493, S494, N501 and Y505 of RBD played a key role in the recognition and affinity of CoV to ACE-2 [47] . Amino acid residues of RBD and the amino acid motif of ACE2 responsible for the interactions were used for molecular screening design. Effective ACE2 receptor antagonists would block the binding of SARS-CoV-2 through competition.

The model of SARS-CoV-2 S-ACE2 complex (PDB ID: 7DF4, http://www1.rcsb.org) was used as the model for molecular docking. 7DF4 was a complex of spike protein trimer and the human ACE2 receptor protein, the structure was solved by electron microscopy with 3.80 Å resolution [48] . Spike protein and ACE2 were separated from the complex and used as independent receptors for molecular docking screening, respectively. The study was confined to molecular docking without validation by molecular dynamics (MD) simulations.

The RBD of SARS-CoV-2 includes amino acid residues 318-510 [49] . According to the protein-protein interface of complex 7DF4, amino acid residues VAL-503, GLY-502, GLN- 

The molecular docking experiment was carried out by AutoDock Vina software. Before docking experiments, water was removed from spike protein and ACE2 receptor protein, then hydrogens were added to the macromolecular receptor, followed by charge calculation and atoms type assign. M2M was used to optimize the structure of ligand molecules to obtain the lowest energy conformation. After docking, the conformations with the lowest binding energies were chosen antagonist candidates. The dual antagonists were screened in 28 natural plant active ingredients. 

Menthol formed hydrogen bonds with GLN-102 and SER-77, formed hydrophobic interaction with LEU-73, TRP-69 and ASN-103. Chrysophanol binds to ACE2 by hydrogen bonds with SER-511 and HIS-505, formed π-π interaction with TRY-510. The ACE2 receptor binding sites of 15 compounds were shown in Fig. 2. 

As to the ACE2 receptor, the lowest binding energy was got by Oleanolic acid with -7.1 kcal/mol, followed by Phellodendrine, Berberine, Tryptanthrin and Quercetin. For spike protein，the binding energy of Tryptanthrin -4.37 kcal/mol was the lowest, followed by Chrysophanol, Rhein, Scopoletin and Oleanolic acid. The number of hydrogen bonds is related to the binding energy. The more the hydrogen bonds, the lower the binding energy.

Hydrogen bond has a strong stabilizing effect on the binding of antagonists to receptors. From the perspective of binding energy, Oleanolic acid, Tryptanthrin, Chrysophanol and Rhein are potential dual antagonists against SARS-CoV-2 By simultaneously blocking the virus spike protein and virus receptor ACE2, respectively.

The molecular dynamics simulations of antagonists have not been carried out yet, the study did not consider the possible flexibility and the exposition [50] of the interface residues of RBD predictions. The binding energy of potential dual antagonists were shown in Fig. 3 . 

SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population

COVID-19: Developing from an Outbreak to A Pandemic

SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta

Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review

Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus

Genomic characterization of a novel SARS-CoV-2

Counterpoint: Activation of the Intrarenal Renin-Angiotensin System is the Dominant Contributor to Systemic Hypertension

Cerebral Salt Wasting: Pathophysiology, Diagnosis, and Treatment

Ang II (Angiotensin II) Conversion to

-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent

A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Hydrolysis of Biological Peptides by

The ACE2/Angiotensin

Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease

Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus

Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis

Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus

Development of a SARS-CoV-2-derived receptor-binding domainbased ACE2 biosensor

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis

Associations of cereal grains intake and Rural Epidemiology study: prospective cohort study

MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes

Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity

A Human Homolog of Angiotensin-converting Enzyme: CLONING AND FUNCTIONAL EXPRESSION AS A CAPTOPRIL-INSENSITIVE CARBOXYPEPTIDASE*

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2

Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity

Research Progress of Traditional Chinese Medicine Against COVID-19

Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts

Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. Viruses

A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)

Volatiles Profiling in Medicinal Licorice Roots Using Steam Distillation and Solid-Phase Microextraction (SPME) Coupled to Chemometrics

Multi-targeting Andrographolide and its Natural Analogs as Potential Therapeutic Agents

Baicalin ameliorates oxidative stress and apoptosis by restoring mitochondrial dynamics in the spleen of chickens via the opposite modulation of NF-κB and Nrf2/HO-1 signaling pathway during Mycoplasma gallisepticum infection

Baicalin inhibits autophagy induced by influenza A virus H3N2

A new coumarin derivative plays a role in rhabdoviral clearance by interfering glycoprotein function during the early stage of viral infection

In vitro antioxidant and anti-inflammatory activities of Radix Isatidis extract and bioaccessibility of six bioactive compounds after simulated gastro-intestinal digestion

Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2

In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain

Authors wish to thank general projects of scientific research plan of Beijing MunicipalCommission of Education for financial support under the project KM202010858002.

J o u r n a l P r e -p r o o f